Jump to content

Search the Community

Showing results for tags 'screening'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • WELCOME NEW MEMBERS!
    • INTRODUCE YOURSELF!
  • STORIES OF SURVIVORSHIP
    • SHARE YOUR LUNG CANCER STORY
  • DISCUSSION FORUMS
    • GENERAL
    • LC SURVIVORS
    • NSCLC GROUP
    • SCLC GROUP
    • US VETERANS
    • CAREGIVER RESOURCE CENTER
  • TREATMENT FORUMS
    • CHEMOTHERAPY
    • IMMUNOTHERAPY
    • RADIATION
    • SURGERY
    • SUPPORTIVE CARE
  • LUNG CANCER NAVIGATOR
    • LUNG CANCER NAVIGATOR
  • NEWS / ADVOCACY
    • LUNG CANCER IN THE NEWS
    • ADVOCACY
  • LIVING WELL
    • HEALTHY LIVING / RECIPES
    • HOPE
    • JUST FOR FUN
  • SUPPORT
    • SUPPORT RESOURCES
  • GRIEF
    • GRIEF
  • TERMS OF USE
    • FEATURES AND SUPPORT

Blogs

  • An Advocates Perspective
  • Cheryncp123's Blog
  • Stay The Course
  • Lung Cancer Stories
  • Spree
  • Volunteer Voices
  • Caregivers Connection
  • Stage IV Treatment With S.B.R.T.
  • Susan Cornett
  • Robin S
  • Lung Cancer & Health Insurance: Tips on managing the mayhem.
  • Daze of My Life by Ken Lourie
  • CommUNITY Connection
  • Heather Smith
  • Lisa Haines
  • Veteran's Oprions
  • Cancer: holding his hand until his last breath
  • A Healthy Place
  • Lenny Blue
  • The Roscopal Effect
  • Ro
  • Sharron P
  • Loi ich suc khoe cua qua chi tu
  • Shanesga
  • Facts are stubborn things, but statistics are pliable

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


First name


Last name


City


Province or district (if non-US)


Postal code


Country


Interests

Found 9 results

  1. Here is the weekly clip report: OncLive “Dr. Larner on Integrating Radiation Therapy With Immune Checkpoint Blockade in NSCLC” https://www.onclive.com/onclive-tv/dr-larner-on-integrating-radiation-therapy-with-immune-checkpoint-blockade-in-nsclc Diagnostic Imaging “Low Dose CT Lung Cancer Screening Program Findings Similar to National Trial” http://www.diagnosticimaging.com/di-executive/low-dose-ct-lung-cancer-screening-program-findings-similar-national-trial Targeted Oncology “Immunotherapy and Chemotherapy Combos Are the New Standard of Care for NSCLC, Says Konduri” https://www.targetedonc.com/news/immunotherapychemotherapy-combos-are-the-new-standard-of-care-for-nsclc-says-konduri OncLive “Dr. Jotte on the Optimal Frequency of Lung Cancer Screening” https://www.onclive.com/onclive-tv/dr-jotte-on-the-optimal-frequency-of-lung-cancer-screening Targeted Oncology “Immunotherapy Combinations Are Changing the Frontline Treatment of Patients With NSCLC” https://www.targetedonc.com/publications/targeted-therapy-news/2018/August-2018/immunotherapy-combinations-are-changing-the-frontline-treatment-of-patients-with-nsclc Cancer Therapy Advisor “Heterogeneity of Drug Resistance in EGFR-Mutant Non-Small Cell Lung Cancer” https://www.cancertherapyadvisor.com/lung-cancer/lung-cancer-nsclc-heterogeneity-drug-resistance-egfr/article/786470/ Speciality Pharmacy Times First Checkpoint Inhibitor for Previously Treated Patients with SCLC Approved by FDA https://www.specialtypharmacytimes.com/news/first-checkpoint-inhibitor-for-previously-treated-patients-with-sclc-approved-by-fda
  2. Here is the weekly clip report: Cure “Lung Cancer Care Becoming More Personalized and Trials will Too” https://www.curetoday.com/articles/lung-cancer-care-becoming-more-personalized-and-trials-will-too Cancer Therapy Advisor “Lurbinectedin Receives FDA Orphan Drug Status for Recurrent Small-Cell Lung Cancer” https://www.cancertherapyadvisor.com/lung-cancer/lung-cancer-nsclc-lurbinecedin-fda-oprhan-drug-status-treatment/article/786009/ U.S. News – Health “What to Know about Lung Cancer Screening Guidelines” https://www.nga.org/governors/addresses/ Healio “Minimally Invasive Surgery Effective for Early-Stage Lung Cancer” https://www.healio.com/hematology-oncology/lung-cancer/news/in-the-journals/{924a7fc0-fcda-4ffb-bad7-4f2cb101c1db}/minimally-invasive-surgery-effective-for-early-stage-lung-cancer Onc Live “Dr. Witsuba on Biomarkers for Immunotherapy in Lung Cancer” https://www.onclive.com/onclive-tv/dr-wistuba-on-biomarkers-for-immunotherapy-in-lung-cancer Drug Target Review “Reducing NOVA1 Helps prevents Tumour Growth in Lung Cancer” https://www.drugtargetreview.com/news/34089/reducing-nova1-lung-cancer/ Science Daily “Finally, a Potential New Approach against KRAS-Driven Lung Cancer” https://www.sciencedaily.com/releases/2018/08/180809093458.htm Oncology Nurse Advisor “New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab” https://www.oncologynurseadvisor.com/lung-cancer/pdl1-inhibitors-for-nsclc-focus-on-pembrolizumab/article/787627/
  3. LUNGevity is proud to announce that the Foundation is serving on three subcommittees of Sustainable Healthy Communities, LLC, founded by the National Minority Quality Forum. As one of two US patient advocacy organizations on the Diverse Cancer Communities Working Group (CWG), LUNGevity will bring years of expertise in supporting the lung cancer community to the Cancer Index Subcommittee, the Community and Patient Engagement Subcommittee, and the Diversity in Clinical Research Subcommittee. “We are proud to work with LUNGevity on the Cancer Working Group, given the importance of always asking for and listening to the patient point of view,” said Jeanne M. Regnante, Chair of the CWG. The overarching goal of the Working Group is to ‘spotlight existing inequities in order to identify and deliver solutions to eliminate barriers to lung cancer screening, referral to appropriate healthcare providers, access to treatment, care, support and inclusive cancer research for all.’ Members of the SHC Working Group include national leaders in pharmaceuticals, government, academia, patient advocacy organizations and life sciences. “We’re especially honored to be working with SHC and its partners on eliminating disparities in detection and treatment for cancer patients,” said Andrea Ferris, CEO of LUNGevity. “To achieve our vision of a world where no one dies of lung cancer, we continually strive to identify unreached populations and supply them with information and tools they need to improve their access to care.” Ms. Ferris will be a speaker at the 2018 NMQF Leadership Summit on Health Disparities and Spring Health Braintrust in Washington, DC this April. She and Upal Basu Roy, PhD, MPH, LUNGevity Director of Translational Research Program/Director of Patient FoRCe, will represent the Foundation on the three subcommittees and all future initiatives. Click here to read the full press release.
  4. Here is the weekly clip report: USA Today “Bristol-Myers Squibb Claims ‘Breakthrough’ Lung Cancer Treatment” https://www.usatoday.com/story/money/2018/02/05/bristol-myers-squibb-claims-breakthrough-lung-cancer-treatment/306433002/ Forbes “Genprex Launch IPO for Trials of New Gene Therapy Lung Cancer Treatment” https://www.forbes.com/sites/rodnturner/2018/02/05/genprex-launch-ipo-for-trials-of-new-gene-therapy-lung-cancer-treatment/#167f00d449fd Cure Today “Not All Small-Cell Lung Cancer Treatment is Equal” https://www.curetoday.com/articles/not-all-small-cell-lung-cancer-treatment-is-equal Targeted Oncology “Gray Sheds Light on Considerations When Treating NSCLC with Immunotherapy” http://www.targetedonc.com/news/gray-sheds-light-on-considerations-when-treating-nsclc-with-immunotherapy Oncology Nurse Advisor “Lung Cancer Screening: Risk-Targeting Approach vs NLST Eligibility Criteria” https://www.oncologynurseadvisor.com/lung-cancer/risk-targeting-approach-vs-national-lung-screening-trial-eligibility-criteria/article/741924/ OncLive “Dr. Erhunmwunsee on Factors of Disparity in Lung Cancer Treatment” http://www.onclive.com/onclive-tv/dr-erhunmwunsee-on-factors-of-disparity-in-lung-cancer-treatment News Medical “LUNGevity Foundation Launches Initiative to Promote Stronger Adherence to Lung Cancer Screening” https://www.news-medical.net/news/20180207/LUNGevity-Foundation-launches-initiative-to-promote-stronger-adherence-to-lung-cancer-screening.aspx Healio “ASCO Panel: Precision Medicine in Practice Can Be Challenging” https://www.healio.com/hematology-oncology/practice-management/news/online/{29cffa20-1d9b-41e1-84e1-804341997d73}/asco-panel-precision-medicine-in-practice-can-be-challenging The Daily Telescope “Dr. Julie Brahmer, M.D., M.Sc. Is Named Professional of the Year by the International Assoc. of Who’s Who” http://dailytelescope.com/pr/dr-julie-r-brahmer-m-d-m-sc-is-named-professional-of-the-year-by-the-international-assoc-of-whoaes-who/66790 UCLA Health “A Double Dose of Promising Lung Cancer Findings” https://www.uclahealth.org/u-magazine/body.cfm?id=17&action=detail&ref=1137 NPR “What Not to Say to the Terminally Ill: ‘Everything Happens for a Reason’” https://www.npr.org/sections/health-shots/2018/02/08/583774624/what-not-to-say-to-the-terminally-ill-everything-happens-for-a-reason
  5. Here is the weekly clip report: PR Newswire “American College of Chest Physicians Publishes New Lung Cancer Screening Guidelines” https://www.prnewswire.com/news-releases/american-college-of-chest-physicians-publishes-new-lung-cancer-screening-guidelines-300589650.html The ASCO Post “Durvalumab Takes a Giant Leap into Stage III NSCLC” http://www.ascopost.com/issues/january-25-2018/durvalumab-takes-a-giant-leap-into-stage-iii-nsclc/ EurekAlert! “New Radiation Techniques Could Improve Quality of Life for Lung Cancer Patients” https://www.eurekalert.org/pub_releases/2018-01/lhri-nrt012918.php Medical Xpress “Expert Panel Issues New Guidelines for Lung Cancer Molecular Testing” https://medicalxpress.com/news/2018-01-expert-panel-issues-guidelines-lung.html KETV-TV “Radon Awareness Month: Lung Cancer Survivor Thinks Radon Caused It” http://www.ketv.com/article/radon-awareness-month-lung-cancer-survivor-thinks-radon-caused-it/15893580 Oncology Nursing News “Socioeconomic Disparity in Lung Cancer Care” http://www.oncnursingnews.com/web-exclusives/socioeconomic-disparity-in-lung-cancer-care OncLive “Treatment of Locally Advanced NSCLC” http://www.onclive.com/insights/multimodal-advanced-nsclc/treatment-of-locally-advanced-nsclc OncLive “Treatment of Early-Stage NSCLC” http://www.onclive.com/insights/multimodal-advanced-nsclc/treatment-of-early-stage-nsclc Cure Today “Who Wears the Face of Cancer?” https://www.curetoday.com/community/bonnie-annis/2018/01/who-wears-the-face-of-cancer Pittsburgh Post-Gazette “LUNGevity Foundation Announces Initiative to Save Lives Through Increased Adherence to Lung Cancer Screening” http://markets.post-gazette.com/postgazette/news/read/35699542/lungevity_foundation_announces_initiative_to_save_lives_through_increased_adherence_to_lung_cancer_screening EurekAlert! “Small Molecule Plays a Big Role in Reducing Cancer’s Spread” https://www.eurekalert.org/pub_releases/2018-01/mcog-smp013018.php KIMT-TV “Lung Cancer Survivor Heads to Super Bowl 52” http://www.kimt.com/content/news/Lung-cancer-survivor-heads-to-Super-Bowl-52-471847253.html The New York Times “After a Cancer Diagnosis, Playing the Odds” https://www.nytimes.com/2018/01/31/well/live/after-a-cancer-diagnosis-playing-the-odds.html Targeted Oncology “Will Combination Therapy with Immunotherapy Become the New Standard of Care for NSCLC?” http://www.targetedonc.com/news/will-combination-therapies-with-immunotherapy-become-the-new-standard-of-care-for-nsclc MIT News “Fine-Tuning Cancer Medicine” http://news.mit.edu/2018/fine-tuning-cancer-medicine-0201 Medical Xpress “Early Access to Palliative Care Associated with Better Quality of Life” https://medicalxpress.com/news/2018-02-early-access-palliative-quality-life.html Medical Xpress “Clinical Trial Tests Feasibility of Targeting Particular Classes of Tumor Types with Certain Drugs” https://medicalxpress.com/news/2018-02-clinical-trial-feasibility-classes-tumor.html
  6. LUNGevity Foundation announced the launch of Project ACTS – Increasing Adherence to CT Screening for lung cancer – a multi-stakeholder project funded by a grant from Bristol-Myers Squibb Foundation through their Bridging Cancer CareTM initiative. Project ACTS will develop and evaluate tools to promote stronger adherence to lung cancer screening protocols so that patients can fully benefit from potentially lifesaving CT screening. Since 2013, the United States Preventive Services Task Force has recommended that people at high risk for lung cancer obtain a low-dose CT scan to detect lung cancer early, when it is most treatable. Currently, there are more than 1,600 American College of Radiology-accredited lung cancer screening centers in the US. However, studies indicate that as many as 45% of screening program participants may not receive appropriate follow-up after an abnormal scan. Through a multi-pronged approach including qualitative studies and the development and testing of engagement tools, Project ACTS seeks to increase the number of individuals who benefit from CT screening-based early detection, thereby saving thousands of lives. Andrea Ferris, CEO of LUNGevity, said, “We are excited to further advance our focus on early detection by creating tools to ensure patients come back for a follow-up scan. The National Lung Screening Trial paved the way to make CT screening available to individuals at high risk for lung cancer. Project ACTS complements the efforts of fellow lung cancer groups, such as the Lung Cancer Alliance, which are setting up Screening Centers of Excellence throughout the country. We thank Bristol-Myers Squibb Foundation for funding this program, which will save lives.” The project is a collaborative effort between LUNGevity Foundation and health psychologist Dr. Jamie Studts from University of Kentucky Markey Cancer Center and health economist Dr. Margaret Byrne from Moffitt Cancer Center in Tampa, FL. “With Project ACTS, the investigative team will develop and begin to test an intervention toolkit that lung cancer screening programs can use to reduce non-adherence, an emerging challenge that could compromise the potential benefits of lung cancer screening on population health,” said Studts. The study team also includes world-renowned pulmonologists Dr. Pierre Massion from Vanderbilt-Ingram Cancer Center and Dr. Peter Mazzone from Cleveland Clinic Foundation as clinician advisors. It is expected to start by the beginning of February 2018 and will involve the development of patient engagement tools that will provide accurate information about screening results and help individuals have meaningful discussions with their healthcare providers after their first CT scan, with the goal of supporting their efforts to return for follow-up scans. “Lack of adherence to screening protocols can have dramatic effects for individuals who could have had disease detected at an earlier, more treatable stage,” said John Damonti, President of the Bristol-Myers Squibb Foundation. “Project ACTS will address the patient engagement challenge to increase adherence to follow-up scans for high risk individuals. We are proud of what this partnership’s work will do to support patients in benefitting from potentially lifesaving screening.” Read the full press release here.
  7. The other day, in conversation with a newly minted medical school graduate, he told me low-dose computed tomography (LDCT) was dangerous. Dangerous! If LDCT is dangerous, what is late discovery of lung cancer? He nearly fainted when I told him I had perhaps more than 40 CT scans in my treatment history, telling me I was a candidate for radiation induced cancer. It didn’t seem to register that I was a candidate for extinction by lung cancer. We are told the only effective way of treating our disease is early discovery. Few dispute this point. Why then would the Center for Medicare & Medicaid Services (CMS) want to reduce reimbursement for low-dose computed tomography (LDCT) screening by more than 40 percent? The Society of Thoracic Surgeons is concerned calling LDCT a “game changer in the battle against lung cancer.” Then I read: “Family physicians lack sufficient knowledge about recommendations for LDCT." Moreover, Doctors Patz and Chen, professors of radiology at Duke, say: “Not screening patients annually could save millions in health care costs and spare patients the radiation exposure and downstream effects of false positive screenings.” Something is very wrong. We have an effective tool for early discovery of life-threatening disease when not discovered early, and there is a campaign mounted against using it. CMS is a federal government-funded agency. In government programs there is a big difference between savings (cash you can put in the bank) and avoidance (cash spent elsewhere). CMS money is appropriated in broad categories. Once appropriated, fiscal managers move money around to address other needs or requirements. Appropriated federal funds are almost never returned to the Treasury. So the reduced funding for LDCT will be a bill payer for some other CMS program. No money is saved; it is spent on something else. Further, when making a valid cost avoidance argument, one must identify all cost. For example, the professors of radiology predicting savings for reduced screening do not identify the millions of dollars of increased cost for treating late-stage-diagnosed lung cancer. A cost avoided almost always results in cost added somewhere else, and without disclosing added burden, professionals are making very unprofessional arguments. Lastly, and most importantly, no one advocating reducing LDCT is considering the most important impact—suffering. There is a vast amount with late-stage diagnosis. Suffering affects more than the lung cancer survivor; it devastates families. While real and detrimental, suffering defies quantification in dollars. Several hundreds-of-thousands of us in the United States will suffer a late-stage lung cancer diagnosis this year. LDCT can eliminate some of this. In this light, it is hard to understand the assault against using LDCT to find, fix, and finish lung cancer! Stay the course.
  8. NY - Free lung screenings are available to those who meet eligibility requirements. http://www.claxtonhepburn.org/se…/lung-cancer-screening.aspx
  9. Hi everyone, This came though my email and I thought I would share it with you. Saint Francis Medical Center is offering a free CT screening for those who qualify. Please share this information with those you know who live in the Illinois area. Please call the lung screening nurse at 309.683.4939 to see if you qualify for a free low dose CT Lung Cancer Screening today! OSF Saint Francis Medical Center530 NE Glen Oak Ave. Peoria, IL 61637 Phone: (309) 655-2000 https://www.osfhealthcare.org/saint-francis/services/pulmonology/ct-lung-cancer-screening/
×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.